Developer docs
API playgroundTry for free, no card

Search company profiles

ATTOM

Full company profile

uuid00r43oe

Namestring
ATTOM
Legal namestring
ATTOM
Websiteurl
attom.eu
Company typeenum
Private
Founded yearint
1996
Descriptiontext

ATTOM SAS is a French medical-device engineering firm headquartered in Villeurbanne (Lyon metropolitan area), founded in 2016 and structured as a Société par Actions Simplifiée with €11,250 of share capital. The company operates an ISO 13485-certified R&D center and engineering office dedicated to the health sector, providing services across four lifecycle phases — ideation, maturation, development, and industrialization — that include market study, rapid prototyping, technical specifications, solution design, in vitro and in vivo validation, pre-series production, and scale-up support.

ATTOM positions itself as a single point of contact for medical-device innovation projects, covering regulatory, quality, and intellectual-property concerns alongside the engineering workstream. Its disclosed reference portfolio spans dental laboratories and industrials (LIO, Dentsply Sirona), regenerative medicine (Healshape), optical devices (Laclarée), biomechanics research (BioMeca), public research and technology-transfer bodies (CEA, SATT Nord), and clinical institutions (CHU de Nantes, Centre Léon Bérard, ICO).

The firm employs 11-50 people and operates from a single French site. Revenue model, pricing structure, contract terms, and funding history are not disclosed in the source materials; the available information supports a description of a small French B2B engineering-services business in the medtech value chain, not a scaled product or platform company.

Short descriptiontext

ATTOM SAS is a French ISO 13485-certified medical device engineering firm in Villeurbanne that runs R&D and industrialization projects for health-sector clients across dental, regenerative medicine, research, and clinical end-markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVilleurbanne, France
HQ citystring
Villeurbanne
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
medical device R&D, medical device engineering, ISO 13485 certification, medical device prototyping, industrialization services
Industry1 code
PRIMARYHLAGAKAL
Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
NAICS code1 code
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Medical Device R&D Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Property Data Licensing
TypeSubscription Recurring
Description

ATTOM provides property data to industries including real estate, mortgage lending, insurance, and government through APIs, bulk data licensing, and cloud-based systems for automated valuation, risk assessment, and market analysis

attomdata.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1ATTOM Intelligence
Description

AI-driven property data framework providing AI-Ready Property Data covering 160 million U.S. properties with flexible delivery options including APIs, cloud platforms, and MCP Server integration

attomdata.com
Core offering1 text field

ATTOM provides medical device R&D, engineering, prototyping, and industrialization services to health-sector clients. The company operates an ISO 13485 certified R&D center and engineering office, delivering a four-phase methodology covering ideation, maturation, development, and industrialization, with regulatory, quality, and intellectual property support across the full project lifecycle.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

ATTOM is a U.S. property data provider offering a comprehensive data platform covering 158-160 million residential and commercial properties (99% of the population). The core offering is the ATTOM Intelligence framework and Property Data Platform, which delivers property data via flexible options including APIs, bulk data licensing, and cloud integrations with Snowflake and Databricks. The portfolio includes the AI-native MCP Server for LLM integration and, following the ResiShares acquisition, institutional-grade analytics and forecasting capabilities including price/rent forecasts and neighborhood-level performance analytics. The platform serves real estate, mortgage lending, insurance, and government sectors with automated valuation, risk assessment, and market analysis capabilities.

Product and service1 record
1Medical Device R&D Services
CategoryMedical Device R&D Services
Description

End-to-end research and development services for medical devices, delivered through a four-phase methodology: Ideation (field observation, brainstorming, market study), Maturation (technical specifications, rapid prototyping, user testing), Development (solution design, performance verification, in vitro and in vivo validation), and Industrialization (pre-series, scale-up, continuous improvement). Includes regulatory, quality, and intellectual property advisory support across the project lifecycle. Delivered by an ISO 13485 certified R&D center for clients in medical devices, dental, regenerative medicine, optical devices, and biomechanics.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-02
Description

ATTOM integrated with Snowflake cloud platform to deliver property data optimized for AI workflows, enabling customers to access ATTOM's comprehensive property datasets directly within their Snowflake environment.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-02
Description

ATTOM expanded cloud data delivery through Databricks, providing direct access to ATTOM's property datasets for analytics and AI-driven workflows within the Databricks Lakehouse platform.

3AI/LLM Systems (MCP Server)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-29
Description

MCP Server enables large language models and AI systems to securely retrieve structured property data through the Model Context Protocol standard.

prnewswire.com
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-01-20
Description

ATTOM acquired key assets of ResiShares including its analytics platform and proprietary technology to strengthen competitive position by adding institutional-grade analytics and forecasting capabilities including price and rent forecasts and neighborhood-level performance analytics.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

International life sciences testing group with medical device testing and certification capabilities. Comparable to ATTOM because it operates in the same ISO 13485-adjacent space of laboratory and quality services for medical device manufacturers, albeit at much larger scale.

TypeDirect peer
Description

French consulting firm specialized in medical device regulatory affairs, quality systems, and clinical evaluation. Comparable to ATTOM because it offers the regulatory and quality compliance layer of medical device development that ATTOM embeds in its end-to-end methodology.

TypeBroad incumbent
Description

Global testing, inspection, and certification firm with a dedicated medical device services portfolio. Comparable because it provides regulatory, quality, and testing services across the medical device development lifecycle, similar to ATTOM's ISO 13485-aligned offering, though at vastly greater scale and broader geographic reach.

TypeBroad incumbent
Description

Swiss-based testing and certification conglomerate with significant medical device testing and regulatory compliance services. Comparable to ATTOM because it serves medical device manufacturers with quality, regulatory, and product-testing support across development and industrialization phases.

TypeBroad incumbent
Description

Global quality assurance provider with medical device testing, certification, and regulatory advisory services. Comparable to ATTOM because it supports medical device clients through testing, regulatory, and quality programs spanning development and market entry.

TypeBroad incumbent
Description

Global CRO with medical device and diagnostic testing services, including biocompatibility and sterilization testing. Comparable to ATTOM because its medical device segment provides in-vitro testing and quality services aligned with ATTOM's development-phase validation activities.

TypeBroad incumbent
Description

Global CRO/CDMO with medical device testing and regulatory services alongside its larger pharmaceutical franchise. Comparable to ATTOM because it serves medical device manufacturers with R&D support, testing, and regulatory services across the development lifecycle.

TypeBroad incumbent
Description

International testing, inspection, and certification company with medical device regulatory and quality services. Comparable to ATTOM because it addresses the same regulatory, quality engineering, and conformity-assessment needs of medical device manufacturers, but as part of a much broader TIC portfolio.

TypeRegional player
Description

French precision engineering and sensor company with a medical device division providing R&D, miniaturization, and industrialization support. Comparable to ATTOM because it serves French medical device clients across prototyping and industrialization, similar to ATTOM's service offering.

TypeDirect peer
Description

Specialized medical device and pharmaceutical testing laboratory offering sterilization, biocompatibility, and packaging validation services. Comparable to ATTOM because it provides the same in-vitro/in-vivo validation and quality testing services that ATTOM includes in its Development phase.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
Yes

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ATTOM

Medical Device R&D Servicesattom.eu

ATTOM SAS is a French ISO 13485-certified medical device engineering firm in Villeurbanne that runs R&D and industrialization projects for health-sector clients across dental, regenerative medicine, research, and clinical end-markets.

What ATTOM does

ATTOM SAS is a French medical-device engineering firm headquartered in Villeurbanne (Lyon metropolitan area), founded in 2016 and structured as a Société par Actions Simplifiée with €11,250 of share capital. The company operates an ISO 13485-certified R&D center and engineering office dedicated to the health sector, providing services across four lifecycle phases — ideation, maturation, development, and industrialization — that include market study, rapid prototyping, technical specifications, solution design, in vitro and in vivo validation, pre-series production, and scale-up support.

ATTOM positions itself as a single point of contact for medical-device innovation projects, covering regulatory, quality, and intellectual-property concerns alongside the engineering workstream. Its disclosed reference portfolio spans dental laboratories and industrials (LIO, Dentsply Sirona), regenerative medicine (Healshape), optical devices (Laclarée), biomechanics research (BioMeca), public research and technology-transfer bodies (CEA, SATT Nord), and clinical institutions (CHU de Nantes, Centre Léon Bérard, ICO).

The firm employs 11-50 people and operates from a single French site. Revenue model, pricing structure, contract terms, and funding history are not disclosed in the source materials; the available information supports a description of a small French B2B engineering-services business in the medtech value chain, not a scaled product or platform company.

ATTOM firmographics

Firmographics
Name
ATTOM
Legal name
ATTOM
Website
https://attom.eu
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
11–50 employees
Short description
ATTOM SAS is a French ISO 13485-certified medical device engineering firm in Villeurbanne that runs R&D and industrialization projects for health-sector clients across dental, regenerative medicine, research, and clinical end-markets.
Ownership category
akta.pro rank

ATTOM industry classification

Industry
Product category
Medical Device R&D Services
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAKAL
Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

  • Medical device R&D
  • Medical device engineering
  • ISO 13485 certification
  • Medical device prototyping
  • Industrialization services

Where ATTOM is headquartered

Location

Headquarters

HQ city
Villeurbanne
HQ country
France
HQ region
Europe

Markets served

ATTOM business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Property Data Licensing: ATTOM provides property data to industries including real estate, mortgage lending, insurance, and government through APIs, bulk data licensing, and cloud-based systems for automated valuation, risk assessment, and market analysis

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

ATTOM product offering

Product offering

Core offering

ATTOM provides medical device R&D, engineering, prototyping, and industrialization services to health-sector clients. The company operates an ISO 13485 certified R&D center and engineering office, delivering a four-phase methodology covering ideation, maturation, development, and industrialization, with regulatory, quality, and intellectual property support across the full project lifecycle.

Product overview

ATTOM is a U.S. property data provider offering a comprehensive data platform covering 158-160 million residential and commercial properties (99% of the population). The core offering is the ATTOM Intelligence framework and Property Data Platform, which delivers property data via flexible options including APIs, bulk data licensing, and cloud integrations with Snowflake and Databricks. The portfolio includes the AI-native MCP Server for LLM integration and, following the ResiShares acquisition, institutional-grade analytics and forecasting capabilities including price/rent forecasts and neighborhood-level performance analytics. The platform serves real estate, mortgage lending, insurance, and government sectors with automated valuation, risk assessment, and market analysis capabilities.

Differentiator

Problem solved

Functional benefit

Brands

  • ATTOM Intelligence: AI-driven property data framework providing AI-Ready Property Data covering 160 million U.S. properties with flexible delivery options including APIs, cloud platforms, and MCP Server integration

Products and services

  • Medical Device R&D Services End-to-end research and development services for medical devices, delivered through a four-phase methodology: Ideation (field observation, brainstorming, market study), Maturation (technical specifications, rapid prototyping, user testing), Development (solution design, performance verification, in vitro and in vivo validation), and Industrialization (pre-series, scale-up, continuous improvement). Includes regulatory, quality, and intellectual property advisory support across the project lifecycle. Delivered by an ISO 13485 certified R&D center for clients in medical devices, dental, regenerative medicine, optical devices, and biomechanics.

Companies that use ATTOM

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles2 records

ATTOM technology and API

Technology

Technology focussed No

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability4 records

Feature5 records

ATTOM partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and strategic.

  • SnowflakecoreTechnology or Integration · 2 April 2026ATTOM integrated with Snowflake cloud platform to deliver property data optimized for AI workflows, enabling customers to access ATTOM's comprehensive property datasets directly within their Snowflake environment.
  • DatabrickscoreTechnology or Integration · 2 April 2026ATTOM expanded cloud data delivery through Databricks, providing direct access to ATTOM's property datasets for analytics and AI-driven workflows within the Databricks Lakehouse platform.
  • AI/LLM Systems (MCP Server)coreTechnology or Integration · 29 January 2026MCP Server enables large language models and AI systems to securely retrieve structured property data through the Model Context Protocol standard.
  • ResiShares (Acquisition)strategicStrategic or Co-development Partner · 20 January 2026ATTOM acquired key assets of ResiShares including its analytics platform and proprietary technology to strengthen competitive position by adding institutional-grade analytics and forecasting capabilities including price and rent forecasts and neighborhood-level performance analytics.

Scale indicators9 records

Recent moves3 records

Expansion highlights1 record

ATTOM competitors and assessment

Company assessment

Broad incumbents

  • Eurofins Scientific: International life sciences testing group with medical device testing and certification capabilities. Comparable to ATTOM because it operates in the same ISO 13485-adjacent space of laboratory and quality services for medical device manufacturers, albeit at much larger scale.
  • TÜV SÜD: Global testing, inspection, and certification firm with a dedicated medical device services portfolio. Comparable because it provides regulatory, quality, and testing services across the medical device development lifecycle, similar to ATTOM's ISO 13485-aligned offering, though at vastly greater scale and broader geographic reach.
  • SGS: Swiss-based testing and certification conglomerate with significant medical device testing and regulatory compliance services. Comparable to ATTOM because it serves medical device manufacturers with quality, regulatory, and product-testing support across development and industrialization phases.
  • Intertek: Global quality assurance provider with medical device testing, certification, and regulatory advisory services. Comparable to ATTOM because it supports medical device clients through testing, regulatory, and quality programs spanning development and market entry.
  • Charles River Laboratories: Global CRO with medical device and diagnostic testing services, including biocompatibility and sterilization testing. Comparable to ATTOM because its medical device segment provides in-vitro testing and quality services aligned with ATTOM's development-phase validation activities.
  • WuXi AppTec: Global CRO/CDMO with medical device testing and regulatory services alongside its larger pharmaceutical franchise. Comparable to ATTOM because it serves medical device manufacturers with R&D support, testing, and regulatory services across the development lifecycle.
  • Bureau Veritas: International testing, inspection, and certification company with medical device regulatory and quality services. Comparable to ATTOM because it addresses the same regulatory, quality engineering, and conformity-assessment needs of medical device manufacturers, but as part of a much broader TIC portfolio.

Direct peers

  • MD101: French consulting firm specialized in medical device regulatory affairs, quality systems, and clinical evaluation. Comparable to ATTOM because it offers the regulatory and quality compliance layer of medical device development that ATTOM embeds in its end-to-end methodology.
  • Nelson Labs: Specialized medical device and pharmaceutical testing laboratory offering sterilization, biocompatibility, and packaging validation services. Comparable to ATTOM because it provides the same in-vitro/in-vivo validation and quality testing services that ATTOM includes in its Development phase.

Regional players

  • Fogale Nanotech: French precision engineering and sensor company with a medical device division providing R&D, miniaturization, and industrialization support. Comparable to ATTOM because it serves French medical device clients across prototyping and industrialization, similar to ATTOM's service offering.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

ATTOM social profiles

Digital presence

ATTOM compliance and trust

Trust signal

Compliance1 record

ATTOM financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ATTOM leadership team

Management profile

Number of profiles

Profiles1 record

ATTOM subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

ATTOM funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ATTOM M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ATTOM

What does ATTOM do?

ATTOM provides medical device R&D, engineering, prototyping, and industrialization services to health-sector clients. The company operates an ISO 13485 certified R&D center and engineering office, delivering a four-phase methodology covering ideation, maturation, development, and industrialization, with regulatory, quality, and intellectual property support across the full project lifecycle.

Is ATTOM a public or private company?

ATTOM is a private company. It is classified as unknown and is currently operating.

When was ATTOM founded?

ATTOM was founded in 1996. It employs 11 to 50 people.

Where is ATTOM based?

ATTOM is headquartered in Villeurbanne, France, in the Europe region.

How does ATTOM make money?

One revenue line is on record: property Data Licensing.

Who are ATTOM's main competitors?

Broad incumbents on record are Eurofins Scientific, TÜV SÜD, SGS, Intertek, Charles River Laboratories, WuXi AppTec and Bureau Veritas. Direct peers are MD101 and Nelson Labs. Fogale Nanotech is listed as a regional player.

Does ATTOM have an API?

Yes. ATTOM provides flexible delivery options including APIs for accessing property data covering 160 million U.S. properties (99% of the population). The API enables developers and organizations to integrate property data into their applications, automate analysis, and scale property intelligence across industries. Developer documentation is at www.attomdata.com/developer.

What industry is ATTOM in?

ATTOM's product category is Medical Device R&D Services. Its primary akta.pro industry code is HLAGAKAL, Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control). Its NAICS code is 54171 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireHOME PRICES GREW YEAR-OVER-YEAR IN NEARLY HALF OF OPPORTUNITY ZONESProperty data provider ATTOM released its Q1 2026 report on Opportunity Zones, finding that 44.6 percent of the 3,403 analyzed census tracts saw year-over-year median home price growth, slightly below the 47.2 percent growth rate in non-Opportunity Zone tracts. However, a higher share of Opportunity Zone tracts (30.8 percent) experienced double-digit price growth compared to tracts outside the zones (28.6 percent). The report notes that home values inside Opportunity Zones remain significantly below the national median, with only 21.1 percent of tracts reaching or exceeding the $360,000 national median compared to 49.4 percent outside the zones.PR NewswireFORECLOSURE ACTIVITY MAINTAINS GRADUAL ANNUAL CLIMB IN APRIL 2026ATTOM released its April 2026 U.S. Foreclosure Market Report on May 14, showing 42,430 properties with foreclosure filings, down 8 percent from the previous month but up 18 percent from a year ago, with foreclosure starts rising 12 percent annually and completed foreclosures (REOs) increasing 42 percent year over year. CEO Rob Barber noted that while lenders appear to be working through distressed inventory as higher borrowing costs and affordability challenges affect some homeowners, foreclosure activity remains significantly below pre-pandemic levels. Florida, Texas, and California led the nation in foreclosure starts for the month.HousingWireForeclosure filings rise 18% year over year in AprilU.S. foreclosure filings reached 42,430 properties in April, representing an 8% decline from March but an 18% increase compared to April 2025, according to ATTOM's April 2026 U.S. Foreclosure Market Report. Foreclosure starts rose 12% year over year to 28,414, while bank-owned property repossessions increased 42% year over year to 5,098, as lenders worked through distressed inventory amid higher borrowing costs and affordability challenges. Delaware recorded the highest state foreclosure rate at one filing per 1,739 housing units, followed by South Carolina and Florida.PR NewswireATTOM INTRODUCES ATTOM INTELLIGENCE TO POWER THE FUTURE OF PROPERTY DATA AND AI-DRIVEN ANALYTICSATTOM, a property data provider, announced the launch of ATTOM Intelligence, a comprehensive framework designed to structure, deliver, and apply property data in an AI-driven environment. The framework provides AI-Ready Property Data covering 160 million U.S. properties (99% of the population), along with flexible delivery options including APIs, cloud platforms, and MCP Server integration. ATTOM Intelligence represents a long-term investment aimed at helping organizations automate analysis and scale property intelligence across industries.HousingWireEquity-rich home share falls to lowest level since 2021ATTOM reported that 43.3% of mortgaged U.S. residential properties were equity-rich in the first quarter of 2026, falling from 44.6% the prior quarter and marking the lowest level since Q4 2021. Meanwhile, 3.2% of mortgaged properties were classified as seriously underwater, up from 3% in Q4 2025, with the share rising quarter-over-quarter in 44 states and D.C. ATTOM attributed the shift to rising mortgage rates and cooling home prices, stating that equity-rich shares declined in most markets while seriously underwater rates are edging up broadly.AijournHOME SALES PROFITS FELL BELOW 45 PERCENT FOR FIRST TIME IN FIVE YEARSATTOM released its Q1 2026 U.S. Home Sales Report showing homeowner profit margins on typical single-family home and condo sales fell to 44.1 percent, the lowest since Q1 2021 and down from 50.2 percent in Q1 2025. The national median home sales price held steady quarter-over-quarter at $360,000 while the typical home sale generated $110,100 in raw profit, down 6 percent year-over-year. The report attributes the decline to rising mortgage rates compounding a typically slower first-quarter sales season, though margins remain above pre-pandemic levels of around 30 percent.HousingWireUS foreclosure filings rise 26% in Q1 2026, ATTOM saysATTOM reported 118,727 U.S. properties with foreclosure filings in Q1 2026, a 26% year-over-year increase and 6% rise from the prior quarter, with March alone seeing 45,921 filings. Foreclosure starts climbed 20% annually to 82,631 properties and bank repossessions surged 45% to 14,020, reflecting a delayed reckoning as years of loss mitigation and forbearance programs wind down. Industry executives warned that this elevated activity could be condensed into the next two years, raising operational and compliance pressures on mortgage servicers while timelines continue to shorten.AijournAVERAGE SINGLE-FAMILY HOME PROPERTY TAX BILL ROSE 3 PERCENT IN 2025ATTOM released its annual property tax analysis showing that $396.8 billion in property taxes were levied on more than 89.6 million single-family homes in 2025, a 3.7 percent increase from 2024. The average single-family home with an estimated value of $494,231 generated $4,427 in taxes, a 3 percent increase from the prior year, while the national effective tax rate rose to 0.9 percent, the highest since 2020. Regional disparities persist, with homeowners in the Northeast and Midwest facing the heaviest tax burdens, led by states like New Jersey ($10,499 average bill) and Connecticut ($8,901), while Western states offer the lowest effective rates.AttomdataHow ATTOM Is Bridging the Gap Between Property Data and Sophisticated AI WorkflowsATTOM, a property data provider covering 158 million U.S. residential and commercial properties, has integrated with Snowflake and Databricks cloud platforms to deliver property data optimized for AI workflows. The article outlines ATTOM's various data delivery options including APIs, bulk data licensing, and cloud-based systems, serving industries such as real estate, mortgage lending, insurance, and government. The content functions as promotional material describing how companies use these platforms for automated valuation, risk assessment, and market analysis.PR NewswireSOFTENING HOME PRICES STILL STRAIN AFFORDABILITY AS FORECLOSURE AND UNEMPLOYMENT RATES RISEATTOM released its Q4 2025 Housing Risk Report showing Florida counties now top the list of riskiest U.S. housing markets, accounting for 16 of the 50 riskiest counties, surpassing California which had 11. The national median home price hit $365,185 while still historically high, with 55.7% of counties requiring at least a third of annual wages for homeownership costs, and foreclosure and unemployment rates rising year-over-year. Rising foreclosures combined with weakening employment in markets where prices remain elevated may face greater risk going forward.